BTIG Reiterates Buy on Kymera Therapeutics, Maintains $134 Price Target
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsReiterationPrice Target
BTIG analyst Jeet Mukherjee reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and maintains $134 price target.
BTIG analyst Jeet Mukherjee reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and maintains $134 price target.